US · HRTX · BIOTECHNOLOGY
Heron Therapeutics, Inc. (HRTX) intrinsic value and stock valuation
$0.25as of 2026-11-21 · Mkt cap 95.55M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Heron Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values HRTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HRTX’s statements →
Heron Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127M | $107.7M | $86.4M |
| Operating income | -$-2.54M | -$-11.53M | -$-110.61M | -$-174.66M | -$-217.83M |
| Net income | -$-20.2M | -$-13.58M | -$-110.56M | -$-182.02M | -$-220.68M |
| EPSd | -$-121.17K | -$-89.08K | -$-800.41K | -$-1.67M | -$-2.24M |
| Operating cash flow | -$-27.59M | -$-22.53M | -$-58.79M | -$-146.91M | -$-203.35M |
| Capital expenditure | -$-320K | -$-1.71M | -$-1.54M | -$-1.82M | -$-3.02M |
| Free cash flow | -$-27.91M | -$-24.23M | -$-60.33M | -$-148.74M | -$-206.38M |
| Total assets | $255.9M | $233.2M | $222.5M | $251M | $305.7M |
| Total debt | $140.6M | $177.8M | $179.6M | $157.5M | $159.5M |
| Net debt | $112M | $152M | $151M | $142.1M | $69M |
| Total equity | $14.3M | -$-33.65M | -$-33.97M | $13.6M | $77.6M |
| Cash and short-term investments | $46.6M | $59.3M | $80.4M | $84.9M | $157.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127M | $107.7M | $86.4M |
| Cost of revenue | $41.4M | $38.7M | $65.1M | $54.9M | $46M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | $40.3M |
| Research and development expenses | $12.4M | $16.7M | $39.1M | $82.7M | $130.8M |
| Selling, general and administrative expenses | $103.7M | $100.5M | $119.8M | $144.8M | $127.3M |
| Other expenses | $0.00 | $0.00 | $13.6M | $0.00 | $0.00 |
| Operating expenses | $116.1M | $117.2M | $172.6M | $227.5M | $258.2M |
| Cost and expenses | $157.4M | $155.8M | $237.7M | $282.3M | $304.2M |
| Interest income | $0.00 | $3.55M | $3.36M | $1.64M | $430K |
| Interest expense | $0.00 | $6.03M | $3.87M | $2.47M | $2.41M |
| Depreciation and amortization | $2.31M | $2.49M | $2.9M | $2.89M | $3.02M |
| Ebitda | -$-17.88M | -$-5.06M | -$-103.79M | -$-176.66M | -$-215.25M |
| Operating income | -$-2.54M | -$-11.53M | -$-110.61M | -$-174.66M | -$-217.83M |
| Total other income/expenses, net | -$-17.66M | -$-2.05M | $60K | -$-7.37M | -$-2.85M |
| Income before tax | -$-20.2M | -$-13.58M | -$-110.56M | -$-182.02M | -$-220.68M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-20.2M | -$-13.58M | -$-110.56M | -$-182.02M | -$-220.68M |
| Weighted average shares outstanding | $166.7M | $152.5M | $138.1M | $109M | $98.5M |
| Weighted average diluted shares outstanding | $166.7M | $152.5M | $138.1M | $109M | $98.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $46.6M | $59.3M | $80.4M | $84.9M | $157.6M |
| Net receivables | $89.6M | $78.9M | $60.1M | $52.1M | $35.5M |
| Inventory | $92.8M | $53.2M | $42.1M | $54.6M | $48.4M |
| Total current assets | $238.1M | $209M | $188.8M | $205.4M | $254.4M |
| Property, plant and equipment, net | $12.4M | $17.7M | $25.6M | $29.8M | $33.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $17.8M | $24.1M | $33.7M | $45.5M | $51.3M |
| Total assets | $255.9M | $233.2M | $222.5M | $251M | $305.7M |
| Accounts payable | $8.99M | $11.7M | $3.8M | $3.59M | $3.87M |
| Short-term debt | $0.00 | $3.04M | $3.08M | $2.69M | $2.42M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $96.1M | $91.5M | $79.7M | $82.4M | $71.1M |
| Long-term debt | $140.6M | $174.7M | $176.6M | $154.8M | $157.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $145.5M | $175.3M | $176.8M | $155M | $157.1M |
| Capital lease obligations | $0.00 | $3.04M | $5.88M | $8.19M | $10.4M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Common stock | $1.88M | $1.52M | $1.5M | $1.19M | $1.02M |
| Retained earnings | -$-1.94B | -$-1.92B | -$-1.91B | -$-1.8B | -$-1.61B |
| Accumulated other comprehensive income (loss) | $0.00 | $10K | $10K | -$-20K | -$-10K |
| Total equity | $14.3M | -$-33.65M | -$-33.97M | $13.6M | $77.6M |
| Total investments | $18M | $33.5M | $51.7M | $69.5M | $67M |
| Total debt | $140.6M | $177.8M | $179.6M | $157.5M | $159.5M |
| Net debt | $112M | $152M | $151M | $142.1M | $69M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-20.2M | -$-13.58M | -$-110.56M | -$-182.02M | -$-220.68M |
| Depreciation and amortization | $2.31M | $2.49M | $2.9M | $2.89M | $3.02M |
| Stock-based compensation | $10.3M | $13M | $32.9M | $43M | $46.9M |
| Change in working capital | -$-31.88M | -$-27.6M | $16.8M | -$-10.51M | -$-35.08M |
| Accounts receivable | -$-10.71M | -$-18.74M | -$-8.09M | -$-16.55M | $6.35M |
| Inventory | -$-31.05M | -$-11.05M | $12.5M | -$-6.19M | -$-6.48M |
| Accounts payable | -$-2.71M | $8.47M | $10K | -$-580K | $3.28M |
| Net cash provided by operating activities | -$-27.59M | -$-22.53M | -$-58.79M | -$-146.91M | -$-203.35M |
| Investments in property, plant and equipment | -$-320K | -$-1.71M | -$-1.54M | -$-1.82M | -$-3.02M |
| Acquisitions, net | $0.00 | $30K | $10K | $230K | $30K |
| Net cash used for investing activities | $16M | $18.7M | $18M | -$-3.32M | $32.7M |
| Common stock issued | $19.3M | $940K | $29.8M | $75.1M | $7.07M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $14.4M | $940K | $54.1M | $75.1M | $156M |
| Net change in cash | $2.85M | -$-2.88M | $13.3M | -$-75.18M | -$-14.6M |
| Cash at end of period | $28.7M | $25.8M | $28.7M | $15.4M | $90.5M |
| Operating cash flow | -$-27.59M | -$-22.53M | -$-58.79M | -$-146.91M | -$-203.35M |
| Capital expenditure | -$-320K | -$-1.71M | -$-1.54M | -$-1.82M | -$-3.02M |
| Free cash flow | -$-27.91M | -$-24.23M | -$-60.33M | -$-148.74M | -$-206.38M |
Line items
Line items
Line items
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
- CEO
- Craig Alexander Collard
- Employees
- 128
- Beta
- 1.65
Explore
Frequently asked questions
What is the intrinsic value of Heron Therapeutics, Inc. (HRTX)?
InvestorsCraft does not currently publish an intrinsic value for HRTX. How the IC value is calculated.
Is HRTX undervalued?
InvestorsCraft does not publish an undervaluation signal for HRTX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.